EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis

Shogo Nakai, Masato Karayama, Yusuke Inoue, Hideki Yasui, Hironao Hozumi, Yuzo Suzuki, Kazuki Furuhashi, Tomoyuki Fujisawa, Noriyuki Enomoto, Satoshi Funayama, Shintaro Ichikawa, Satoshi Goshima und 2 weitere

Respiratory Investigation · 2025

DOI: 10.1016/j.resinv.2025.02.005 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Respiratory Investigation, 2025. Verfasst von Shogo Nakai und 13 weiteren Autor:innen. Beteiligte Einrichtung: Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan. Hauptthemen laut MEDLINE: Mucin-1, Immune Checkpoint Inhibitors, Pulmonary Surfactant-Associated Protein D, Pneumonia. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 32 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Immune-related pneumonitis (irP) is a severe immune-related adverse event that can occur after treatment with immune checkpoint inhibitors (ICIs); accurate monitoring and early diagnosis are crucial. Serum Krebs von den Lungen-6 (KL-6) and surfactant protein-D (SP-D) are used to diagnose and monitor the disease activity of various types of interstitial lung disease. This study evaluated the usefulness of KL-6 and SP-D for diagnosing irP in cancer patients receiving ICIs. PATIENTS AND METHODS: This retrospective observational study included cancer patients treated with more than two cycles of ICIs from September 2014 to October 2023. Receiver operating characteristic (ROC) analysis was used to assess the diagnostic utility of KL-6 and SP-D. RESULTS: Of the 724 cancer patients, 631 were included in the analysis, and 64 developed irP. The ROC analysis showed that KL-6 and SP-D had areas under the curve of 0.803 and 0.845, respectively. Serum KL-6 ≥ 500 U/mL had a sensitivity of 65.6% and a specificity of 83.4% for the diagnosis of irP, while SP-D ≥ 110 ng/mL had a sensitivity of 66.7% and a specificity of 88.6%. Combining both KL-6 ≥ 500 U/mL and SP-D ≥ 110 ng/mL resulted in a specificity of 96.6%, with a sensitivity of 46.7%. Combining either KL-6 ≥ 500 U/mL or SP-D ≥ 110 ng/mL resulted in a sensitivity of 85.0%, with a specificity of 75.5%. SP-D levels were significantly associated with irP severity, while KL-6 levels were not. CONCLUSIONS: Serum KL-6 and SP-D are useful for diagnosing irP in cancer patients receiving ICIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Mucin-1Immune Checkpoint InhibitorsPulmonary Surfactant-Associated Protein DPneumoniaHumansRetrospective StudiesMaleFemaleMiddle AgedAgedBiomarkersROC CurveNeoplasmsAged, 80 and over

Stichwörter der Autor:innen

Anti-cytotoxic T-lymphocyte-associated protein-4 therapyAnti-programmed death-1 therapyDrug-induced pulmonary diseaseInterstitial lung diseaseInterstitial pneumonia

Substanzen

Mucin-1Immune Checkpoint InhibitorsPulmonary Surfactant-Associated Protein DMUC1 protein, humanBiomarkers

Autor:innen und Institutionen

  • Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.
  • Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan; Department of Chemotherapy, Hamamatsu University School of Medicine, 1-20-1 Handay…
  • Department of Radiology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan.
  • Second Division, Department of Internal Medicine, Hamamatsu University School of Medicine, 1-20-1 Handayama, Hamamatsu, 431-3192, Japan; Department of Clinical Pharmacology and Therapeutics, Hamamatsu University School…

Zitieren

APA

Nakai, S., Karayama, M., Inoue, Y., Yasui, H., Hozumi, H., Suzuki, Y., Furuhashi, K., Fujisawa, T., Enomoto, N., Funayama, S., Ichikawa, S., Goshima, S., Inui, N., & Suda, T. (2025). Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis. Respiratory Investigation. https://doi.org/10.1016/j.resinv.2025.02.005

Vancouver

Nakai S, Karayama M, Inoue Y, Yasui H, Hozumi H, Suzuki Y, et al. Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis. Respiratory Investigation. 2025. doi:10.1016/j.resinv.2025.02.005

BibTeX
@article{Nakai2025,
  author = {Nakai, Shogo and Karayama, Masato and Inoue, Yusuke and Yasui, Hideki and Hozumi, Hironao and Suzuki, Yuzo and Furuhashi, Kazuki and Fujisawa, Tomoyuki and Enomoto, Noriyuki and Funayama, Satoshi and Ichikawa, Shintaro and Goshima, Satoshi and Inui, Naoki and Suda, Takafumi},
  title = {Utility of serum Krebs von den Lungen-6 and surfactant protein-D levels for the diagnosis of immune checkpoint inhibitor-induced immune-related pneumonitis},
  journal = {Respiratory Investigation},
  year = {2025},
  doi = {10.1016/j.resinv.2025.02.005}
}
Kostenlos starten →